CCR2 and neoplasm: It is worth noting that combined treatment with CCR2 inhibitors and CXCR2 inhibitors can overcome this compensatory effect, and augment anti-tumor immunity and improve response to FOLFIRINOX chemotherapy, prolonging the survival of PDAC mice (187).